Literature DB >> 18413396

Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.

Frank Willi Floeth1, Michael Sabel, Gabriele Stoffels, Dirk Pauleit, Kurt Hamacher, Hans-Jakob Steiger, Karl-Josef Langen.   

Abstract

UNLABELLED: Nonspecific incidental brain lesions (NILs) are being detected more frequently because of an increasing number of screening or research MRI scans of the brain, and their natural course is uncertain.
METHODS: In a prospective cohort study starting in 1999, we determined the outcomes of patients with incidental, nonenhancing, supratentorial, lobar, and small-volume (<10 mL) lesions, depending on the findings of MRI and PET with the (18)F-labeled amino acid fluoroethyl-l-tyrosine ((18)F-FET). Patients with seizures, focal neurologic deficits, signs of local or systemic infection or inflammation, known brain disease, or any kind of previous cerebral treatment were excluded. Finally, 21 patients were eligible. MRI was performed in 19 of these patients because of nonspecific symptoms (such as headaches, dizziness, or sudden deafness), whereas 2 patients were healthy volunteers in MRI studies. Clinical follow-up and MRI scans were obtained at 4- to 6-mo intervals, and follow-up ranged from 3 to 8.5 y. Mean lesion-to-brain (L/B) ratios of >or=1.6 on (18)F-FET PET were rated as positive.
RESULTS: Four different outcome groups were identified. In group A, 5 NILs regressed or vanished completely. All of these lesions were circumscribed on MRI, and (18)F-FET uptake was negative, with an L/B ratio of 1.2+/-0.2 (mean +/- SD). In group B, 10 NILs were stable, without growth. All of these lesions were circumscribed on MRI, and (18)F-FET uptake was negative (L/B ratio: 1.0+/-0.1). In group C, 2 NILs grew slowly over years, and an astrocytoma of World Health Organization (WHO) grade II was diagnosed after resection in each case. The lesions were circumscribed on MRI, and (18)F-FET uptake was negative (L/B ratios: 0.7 and 1.0). In group D, 4 NILs showed sudden and rapid growth, with clinical deterioration, and a high-grade glioma of WHO grade III or IV was diagnosed after resection in all cases. The lesions were diffuse on MRI, and (18)F-FET uptake was significantly increased (L/B ratio: 2.0+/-0.4) (P<0.01 for group D vs. group A or group B).
CONCLUSION: For NILs, a circumscribed growth pattern on MRI and normal or low (18)F-FET uptake on PET are strong predictors for a benign course, with the eventual development of a low-grade glioma. In contrast, NILs with a diffuse growth pattern on MRI and increased (18)F-FET uptake indicate a high risk for the development of a high-grade glioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413396     DOI: 10.2967/jnumed.107.050005

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

Review 2.  [Multiparametric imaging with simultaneous MRI/PET: Methodological aspects and possible clinical applications].

Authors:  S Gatidis; H Schmidt; C D Claussen; N F Schwenzer
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

Review 3.  [Multiparametric imaging with simultaneous MR/PET. Methodological aspects and possible clinical applications].

Authors:  S Gatidis; H Schmidt; C D Claussen; N F Schwenzer
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

4.  Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Authors:  Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

Review 5.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

6.  Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Authors:  Florian Stockhammer; Martin Misch; Arend Koch; Marcus Czabanka; Michail Plotkin; Cristiane Blechschmidt; Jochen Tuettenberg; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

7.  Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?

Authors:  Robert Pichler; Andreas Dunzinger; Gabriele Wurm; Josef Pichler; Serge Weis; Karin Nussbaumer; Raffi Topakian; Reingard M Aigner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-16       Impact factor: 9.236

Review 8.  Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Authors:  Guilherme Lucas de Oliveira Lima; Marc Zanello; Emmanuel Mandonnet; Luc Taillandier; Johan Pallud; Hugues Duffau
Journal:  Neurosurg Rev       Date:  2015-11-27       Impact factor: 3.042

9.  [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

10.  18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Authors:  Sied Kebir; Florian C Gaertner; Marcus Mueller; Michael Nelles; Matthias Simon; Niklas Schäfer; Moritz Stuplich; Christina Schaub; Michael Niessen; Frederic Mack; Ralph Bundschuh; Susanne Greschus; Markus Essler; Martin Glas; Ulrich Herrlinger
Journal:  Oncol Lett       Date:  2016-02-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.